Name | BI-2865 |
Description | BI-2865 is a non-covalent pan-KRAS inhibitor.BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively.BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants[1] . BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants, with an average IC50 value of approximately 140 nM.[1] |
In vitro | METHODS: BaF3 cells expressing isogenic KRAS mutants of the indicated KRAS or expressing G12C, G12D or G12V mutant KRAS were treated in the absence of IL3 for 5 days to determine the effect on proliferation.
RESULTS BI-2865 inhibited the proliferation of isogenic G12C, G12D or G12V mutant KRAS expressing BaF3 with an IC50 value of 140 nM. [1] |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 225.0 mg/mL (483.3 mM), Sonication is recommended.
|
Keywords | BI 2865 | BI-2865 | BI2865 |
Inhibitors Related | Adagrasib | (S)-AMG-510 | BI-2493 | CCG-257081 | Ketoconazole | Deltarasin | MRTX1133 | Salirasib | RMC-6236 | (S)-(-)-Perillyl alcohol | CASIN | Sotorasib |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |